**Core Concept**
The question is testing the underlying genetic principle associated with the development of malignant melanoma. Specifically, it is asking about the genetic mutation that is commonly linked to this type of skin cancer.

**Why the Correct Answer is Right**
Malignant melanoma is a type of skin cancer that arises from the pigment-producing cells called melanocytes. A key genetic mutation associated with the development of malignant melanoma is the BRAF V600E mutation. This mutation leads to the substitution of glutamic acid for valine at position 600 in the BRAF protein, which is a downstream effector of the RAS-MAPK signaling pathway. The activation of this pathway promotes cell proliferation and survival, contributing to the development of cancer. The BRAF V600E mutation is present in approximately 50% of malignant melanoma cases and is a key target for targeted therapy.

**Why Each Wrong Option is Incorrect**
**Option A:** This is not a known genetic mutation associated with malignant melanoma.
**Option B:** While mutations in the NRAS gene can also contribute to the development of melanoma, they are not as common as the BRAF V600E mutation.
**Option C:** This is not a recognized genetic mutation related to malignant melanoma.
**Option D:** While TP53 mutations are common in many types of cancer, they are not specifically associated with the development of malignant melanoma.

**Clinical Pearl / High-Yield Fact**
The BRAF V600E mutation is a key target for targeted therapy in malignant melanoma, and patients with this mutation may benefit from treatment with BRAF inhibitors such as vemurafenib.

**Correct Answer:** B. NRAS